Cargando…

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?

Detalles Bibliográficos
Autores principales:	Ricci, Angela Dalia, Rizzo, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706370/ https://www.ncbi.nlm.nih.gov/pubmed/34946246 http://dx.doi.org/10.3390/medicina57121301

Ejemplares similares

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

New and emerging treatment options for biliary tract cancer
por: Noel, Marcus S, et al.
Publicado: (2013)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

The Role of HER2 Status in the Biliary Tract Cancers
por: Ayasun, Ruveyda, et al.
Publicado: (2023)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?
por: Kiesslich, Tobias, et al.
Publicado: (2019)

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option
por: Simone, Valeria, et al.
Publicado: (2017)

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
por: Solinas, Cinzia, et al.
Publicado: (2021)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
por: Personeni, Nicola, et al.
Publicado: (2020)

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
por: Brandi, Giovanni, et al.
Publicado: (2022)

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Bile cell‑free DNA: a game changer for management of biliary tract cancer?
por: Rizzo, A., et al.
Publicado: (2022)

Systemic treatment options for advanced biliary tract carcinoma
por: Xie, Changqing, et al.
Publicado: (2020)

Erratum to: Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
por: Chien, A. Jo, et al.
Publicado: (2012)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Applied precision cancer medicine in metastatic biliary tract cancer
por: Taghizadeh, H., et al.
Publicado: (2020)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
por: Arteaga, Carlos L
Publicado: (2003)

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
por: Gampenrieder, Simon Peter, et al.
Publicado: (2020)

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
por: Candas-Green, Demet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8gjqkhlpugktdq1kek8druaoov